Further long-term studies using NASH model mice with mTOR inhibitors are needed to confirm the postulated relationship between activated mTOR and NASH–HCC progression and elucidate underlying mechanisms. Here, MTOR is linked to metabolic dysfunction-associated steatohepatitis.